Cargando…

Development and validation of a prognostic scoring model for mortality risk stratification in patients with recurrent or metastatic gastric carcinoma

BACKGROUND: Survival times differ among patients with advanced gastric carcinoma. A precise and universal prognostic evaluation strategy has not yet been established. The current study aimed to construct a prognostic scoring model for mortality risk stratification in patients with advanced gastric c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Tai, Wu, Zhijun, Zhang, Xiaopeng, Xu, Hui, Feng, Ying, Zhang, Cheng, Xie, Minmin, Yang, Yahui, Zhang, Yi, Feng, Chong, Sun, Guoping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666033/
https://www.ncbi.nlm.nih.gov/pubmed/34895168
http://dx.doi.org/10.1186/s12885-021-09079-7
_version_ 1784614127533031424
author Ma, Tai
Wu, Zhijun
Zhang, Xiaopeng
Xu, Hui
Feng, Ying
Zhang, Cheng
Xie, Minmin
Yang, Yahui
Zhang, Yi
Feng, Chong
Sun, Guoping
author_facet Ma, Tai
Wu, Zhijun
Zhang, Xiaopeng
Xu, Hui
Feng, Ying
Zhang, Cheng
Xie, Minmin
Yang, Yahui
Zhang, Yi
Feng, Chong
Sun, Guoping
author_sort Ma, Tai
collection PubMed
description BACKGROUND: Survival times differ among patients with advanced gastric carcinoma. A precise and universal prognostic evaluation strategy has not yet been established. The current study aimed to construct a prognostic scoring model for mortality risk stratification in patients with advanced gastric carcinoma. METHODS: Patients with advanced gastric carcinoma from two hospitals (development and validation cohort) were included. Cox proportional hazards regression analysis was conducted to identify independent risk factors for survival. A prognostic nomogram model was developed using R statistics and validated both in bootstrap and external cohort. The concordance index and calibration curves were plotted to determine the discrimination and calibration of the model, respectively. The nomogram score and a simplified scoring system were developed to stratify patients in the two cohorts. RESULTS: Development and validation cohort was comprised of 401 and 214 gastric cancer patients, respectively. Mucinous or non-mucinous histology, ECOG score, bone metastasis, ascites, hemoglobin concentration, serum albumin level, lactate dehydrogenase level, carcinoembryonic antigen level, and chemotherapy were finally incorporated into prognostic nomogram. The concordance indices were 0.689 (95% CI: 0.664 ~ 0.714) and 0.673 (95% CI: 0.632 ~ 0.714) for bootstrap and external validation. 100 and 200 were set as the cut-off values of nomogram score, patients in development cohort were stratified into low-, intermediate- and high-risk groups with median overall survival time 15.8 (95% CI: 12.2 ~ 19.5), 8.4 (95% CI: 6.7 ~ 10.2), and 3.9 (95% CI: 2.7 ~ 5.2) months, respectively; the cut-off values also worked well in validation cohort with different survival time in subgroups. A simplified model was also established and showed good consistency with the nomogram scoring model in both of development and validation cohorts. CONCLUSION: The prognostic scoring model and its simplified surrogate can be used as tools for mortality risk stratification in patients with advanced gastric carcinoma. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-09079-7.
format Online
Article
Text
id pubmed-8666033
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86660332021-12-13 Development and validation of a prognostic scoring model for mortality risk stratification in patients with recurrent or metastatic gastric carcinoma Ma, Tai Wu, Zhijun Zhang, Xiaopeng Xu, Hui Feng, Ying Zhang, Cheng Xie, Minmin Yang, Yahui Zhang, Yi Feng, Chong Sun, Guoping BMC Cancer Research BACKGROUND: Survival times differ among patients with advanced gastric carcinoma. A precise and universal prognostic evaluation strategy has not yet been established. The current study aimed to construct a prognostic scoring model for mortality risk stratification in patients with advanced gastric carcinoma. METHODS: Patients with advanced gastric carcinoma from two hospitals (development and validation cohort) were included. Cox proportional hazards regression analysis was conducted to identify independent risk factors for survival. A prognostic nomogram model was developed using R statistics and validated both in bootstrap and external cohort. The concordance index and calibration curves were plotted to determine the discrimination and calibration of the model, respectively. The nomogram score and a simplified scoring system were developed to stratify patients in the two cohorts. RESULTS: Development and validation cohort was comprised of 401 and 214 gastric cancer patients, respectively. Mucinous or non-mucinous histology, ECOG score, bone metastasis, ascites, hemoglobin concentration, serum albumin level, lactate dehydrogenase level, carcinoembryonic antigen level, and chemotherapy were finally incorporated into prognostic nomogram. The concordance indices were 0.689 (95% CI: 0.664 ~ 0.714) and 0.673 (95% CI: 0.632 ~ 0.714) for bootstrap and external validation. 100 and 200 were set as the cut-off values of nomogram score, patients in development cohort were stratified into low-, intermediate- and high-risk groups with median overall survival time 15.8 (95% CI: 12.2 ~ 19.5), 8.4 (95% CI: 6.7 ~ 10.2), and 3.9 (95% CI: 2.7 ~ 5.2) months, respectively; the cut-off values also worked well in validation cohort with different survival time in subgroups. A simplified model was also established and showed good consistency with the nomogram scoring model in both of development and validation cohorts. CONCLUSION: The prognostic scoring model and its simplified surrogate can be used as tools for mortality risk stratification in patients with advanced gastric carcinoma. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-09079-7. BioMed Central 2021-12-12 /pmc/articles/PMC8666033/ /pubmed/34895168 http://dx.doi.org/10.1186/s12885-021-09079-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ma, Tai
Wu, Zhijun
Zhang, Xiaopeng
Xu, Hui
Feng, Ying
Zhang, Cheng
Xie, Minmin
Yang, Yahui
Zhang, Yi
Feng, Chong
Sun, Guoping
Development and validation of a prognostic scoring model for mortality risk stratification in patients with recurrent or metastatic gastric carcinoma
title Development and validation of a prognostic scoring model for mortality risk stratification in patients with recurrent or metastatic gastric carcinoma
title_full Development and validation of a prognostic scoring model for mortality risk stratification in patients with recurrent or metastatic gastric carcinoma
title_fullStr Development and validation of a prognostic scoring model for mortality risk stratification in patients with recurrent or metastatic gastric carcinoma
title_full_unstemmed Development and validation of a prognostic scoring model for mortality risk stratification in patients with recurrent or metastatic gastric carcinoma
title_short Development and validation of a prognostic scoring model for mortality risk stratification in patients with recurrent or metastatic gastric carcinoma
title_sort development and validation of a prognostic scoring model for mortality risk stratification in patients with recurrent or metastatic gastric carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666033/
https://www.ncbi.nlm.nih.gov/pubmed/34895168
http://dx.doi.org/10.1186/s12885-021-09079-7
work_keys_str_mv AT matai developmentandvalidationofaprognosticscoringmodelformortalityriskstratificationinpatientswithrecurrentormetastaticgastriccarcinoma
AT wuzhijun developmentandvalidationofaprognosticscoringmodelformortalityriskstratificationinpatientswithrecurrentormetastaticgastriccarcinoma
AT zhangxiaopeng developmentandvalidationofaprognosticscoringmodelformortalityriskstratificationinpatientswithrecurrentormetastaticgastriccarcinoma
AT xuhui developmentandvalidationofaprognosticscoringmodelformortalityriskstratificationinpatientswithrecurrentormetastaticgastriccarcinoma
AT fengying developmentandvalidationofaprognosticscoringmodelformortalityriskstratificationinpatientswithrecurrentormetastaticgastriccarcinoma
AT zhangcheng developmentandvalidationofaprognosticscoringmodelformortalityriskstratificationinpatientswithrecurrentormetastaticgastriccarcinoma
AT xieminmin developmentandvalidationofaprognosticscoringmodelformortalityriskstratificationinpatientswithrecurrentormetastaticgastriccarcinoma
AT yangyahui developmentandvalidationofaprognosticscoringmodelformortalityriskstratificationinpatientswithrecurrentormetastaticgastriccarcinoma
AT zhangyi developmentandvalidationofaprognosticscoringmodelformortalityriskstratificationinpatientswithrecurrentormetastaticgastriccarcinoma
AT fengchong developmentandvalidationofaprognosticscoringmodelformortalityriskstratificationinpatientswithrecurrentormetastaticgastriccarcinoma
AT sunguoping developmentandvalidationofaprognosticscoringmodelformortalityriskstratificationinpatientswithrecurrentormetastaticgastriccarcinoma